로딩 중…
StockDiggingStockDigging

Haemonetics Corporation

HAE· NYSE
$120.20+0.46%
2026-11-02

Financials

Valuation Metrics

Haemonetics Corporation's Market Cap is $5.46B. At end of 2025 it was $3.75B. Ranked #1275 of 3,118 in US market (top 41%), #850 of 1,644 on NYSE (top 52%), #83 of 203 in Health Care Equipment & Services (top 41%) by Market Cap.

Investment Metrics(as of 2026-11-02)

MetricValue
Size
Market Cap$5.46B
Revenue$1.35B
Net Income$96M
Total Assets$2.37B
Net Assets$837M
Employees3,023
Value
P/E56.73x
P/B6.53x
P/S4.04x
EV/EBITDA24.55x
FCF Yield5.33%
Profitability
ROE11.50%
ROA4.07%
Op. Margin18.18%
Revenue Growth0.44%
Earnings Growth-41.05%
Financial Health
Debt Ratio182.57%
Total Debt$1.17B
FCF$291M
Cash$223M
Current Ratio3.08x
Net Debt/EBITDA3.64x
Performance
1Y Return140.36%
1M Return14.83%
From 52W High-2.88%
1Y MDD-40.06%
Trading
Volume486,992 shares
Trading Value$59M
Per Share
EPS$2.12
BPS$18.42

Company Info

CEO Mr. Christopher A. Simon
Employees 3,023
HQ Boston, United States

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.